ArticleBMC oral health2026
Hypoxia and angiogenesis across clinical stages of oral submucous fibrosis: implications for oral carcinogenesis.
Article in BMC oral health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background"Oral Submucous Fibrosis" (OSF) is a progressive "potentially malignant disorder" which is characterized by fibrosis and epithelial atrophy, resultant to hypoxia. The resulting hypoxic microenvironment is thought to trigger angiogenic responses that promote disease progression and malignant transformation. This study assessed whether hypoxia (HIF-1α) and angiogenesis (CD105) correlate with clinical stages in OSF.
methodsA total of 105 tissue samples (30 normal oral mucosa; 75 OSF) were analysed using immunohistochemistry. HIF-1α immunoreactice score and CD105 based microvascular metrics, microvessel density "(MVD)", total vascular area "(TVA)", and mean vascular area "(MVA)" were quantified.
resultsHIF-1α expression increased progressively across stages of OSF (p = 0.046). Similarly, CD105 expression, reflected by MVD, TVA, and MVA, demonstrated progressive elevation with disease advancement (p = 0.0001). Both markers demonstrated a positive correlation. (r = 0.62, p < 0.05).
conclusionsThe concurrent upregulation of HIF-1α and CD105 across clinical stages underscores a dynamic interrelationship between hypoxia and angiogenesis in OSF. These findings support integrating molecular markers into staging systems to enhance early association with "malignant transformation".
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.